https://www.theedgemarkets.com/article/chinas-experimental-covid19-vaccine-appears-safe-%E2%80%94-study

Ssm Registered Company:1,300,000 companies
Cost per submission: RM15
Assumption: minimum 1 time submissions for 1 company per yr (correct me if im wrong, im not sure too)
Sales: 1,300,000 x 15 x 1 = 19.5m
PAT: deduct 25% = 14.6m (i havent add up other's income)

Assume PE: 20 (very undervalue for a bright future tech company)

14.6/358 x 20 = 0.815

Less less also RM0.815

On stock selection, after correcting 17.6% from a 22M high of RM0.71 (3 Sep) to RM0.585 yesterday, DNONCE (Not-rated) will be attractive to bargain on any price weakness towards the 0.56 (uptrend line support) and RM0.53 (30D SMA) supports levels. To recap, DNONCE is a diversified engineering solutions provider with key customer base from: 1) Healthcare division mainly serving major glove producers based in Thailand (manufacture packaging boxes for major glove manufacturers and produce plastic products for medical use); 2) E

Topglove is moving up with TS's hints, sales most likely is strong. Since Dnonce is producing the boxes for them, Topglove's sales amount comfirm bring up the Dnonce's sales

Agree with dejavu , topglove sales getting higher n higher, so to this Dnonce as well

Double hammer sign, strong buying signal! Dragged by last few day's market sentiment, time to crush the road block and march in!!

haven't included coming quarter's growth on sales~ it shall be higher!

Assume every quarter also earn RM4m or more or less, so whole year PAT will be RM16m

PE 12

Number of shares: 262m

Price / Earning Ratio = PE

Price = Earning Ratio X PE

16/262 x 12 = 0.73

Since related to Gloves, let say follow current lowest PE 30

16/262 x 30 = 1.83

Fair value on this DNONCE shall be RM1.83

Dpharma PE = 38.38

if solutn pe 38.38 then fair price shall be RM3.84? my two cents